Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April W Armstrong

Showing results (341-350 of 522) with videos related to

Pageof 53
Sort By:
Dermatology and Therapy|June 19, 2024
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic DermatitisApril W Armstrong, Andrew F Alexis, Andrew Blauvelt, et al.
Dermatology and Therapy|January 22, 2024
Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient SurveyApril W Armstrong, Sayeli Jayade, Sanika Rege, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working GroupLourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 22, 2025
GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort studyPeichi P Chou, Charlotte Jeong, Elaine Ma, et al.
Journal of the American Academy of Dermatology|September 24, 2018
A provider global assessment quality measure for clinical practice for inflammatory skin disordersAlice Gottlieb, Nicole Salame, April W Armstrong, et al.
Dermatology Online Journal|April 11, 2023
Differences in accessing dermatology offices, primary care offices, and emergency departments between Hispanics and Non-Hispanic White PatientsCaterina Zagona-Prizio, Sabrina Khan, Danielle K Yee, et al.
The Journal of Dermatological Treatment|July 1, 2020
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United StatesXiaoying Jia, Yang Zhao, Justin Carrico, et al.
Journal of Drugs in Dermatology : JDD|August 9, 2023
No Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United StatesRasika Reddy, Sabrina Khan, Danielle Yee, et al.
Journal of the American Academy of Dermatology|February 25, 2021
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial dataNeil H Shear, Keith A Betts, Ahmed M Soliman, et al.
Dermatology and Therapy|August 29, 2021
Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical RecordsApril W Armstrong, Dhaval Patil, Eugenia Levi, et al.
Pageof 53

Showing results (341-350 of 522) with videos related to

Sort By:
Pageof 53
Dermatology and Therapy|June 19, 2024
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic DermatitisApril W Armstrong, Andrew F Alexis, Andrew Blauvelt, et al.
Dermatology and Therapy|January 22, 2024
Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient SurveyApril W Armstrong, Sayeli Jayade, Sanika Rege, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working GroupLourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 22, 2025
GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort studyPeichi P Chou, Charlotte Jeong, Elaine Ma, et al.
Journal of the American Academy of Dermatology|September 24, 2018
A provider global assessment quality measure for clinical practice for inflammatory skin disordersAlice Gottlieb, Nicole Salame, April W Armstrong, et al.
Dermatology Online Journal|April 11, 2023
Differences in accessing dermatology offices, primary care offices, and emergency departments between Hispanics and Non-Hispanic White PatientsCaterina Zagona-Prizio, Sabrina Khan, Danielle K Yee, et al.
The Journal of Dermatological Treatment|July 1, 2020
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United StatesXiaoying Jia, Yang Zhao, Justin Carrico, et al.
Journal of Drugs in Dermatology : JDD|August 9, 2023
No Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United StatesRasika Reddy, Sabrina Khan, Danielle Yee, et al.
Journal of the American Academy of Dermatology|February 25, 2021
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial dataNeil H Shear, Keith A Betts, Ahmed M Soliman, et al.
Dermatology and Therapy|August 29, 2021
Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical RecordsApril W Armstrong, Dhaval Patil, Eugenia Levi, et al.
Pageof 53